[1]
SungH, FerlayJ, SiegelRL,et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71(3):209-249. DOI: 10.3322/caac.21660.
[2]
HuangJ, PatelHK, BoakyeD,et al. Worldwide distribution, associated factors, and trends of gallbladder cancer: a global country-level analysis[J]. Cancer Lett, 2021, 521:238-251. DOI: 10.1016/j.canlet.2021.09.004.
[3]
HeY, LiangD, LiD,et al. Incidence and mortality of laryngeal cancer in China, 2015[J]. Chin J Cancer Res, 2020, 32(1):10-17. DOI: 10.21147/j.issn.1000-9604.2020.01.02.
[4]
中华医学会外科学分会胆道外科学组, 中国医师协会外科医师分会胆道外科专业委员会. 胆囊癌诊断和治疗指南(2019版)[J]. 中华外科杂志, 2020, 58(4):243-251. DOI: 10.3760/cma.j.cn112139-20200106-00014.
[5]
AlshahriTM, AbounozhaS. Best evidence topic: does the presence of a large gallstone carry a higher risk of gallbladder cancer?[J]. Ann Med Surg (Lond), 2021, 61:93-96. DOI: 10.1016/j.amsu.2020.12.023.
[6]
HuangD, JooH, SongN,et al. Association between gallstones and the risk of biliary tract cancer: a systematic review and Meta-analysis[J]. Epidemiol Health, 2021, 43:e2021011. DOI: 10.4178/epih.e2021011.
[7]
中华医学会外科学分会胆道外科学组, 中国医师协会外科医师分会胆道外科医师委员会. 胆囊良性疾病外科治疗的专家共识(2021版)[J]. 中华外科杂志, 2022, 60(1):4-9. DOI: 10.3760/cma.j.cn112139-20210811-00373.
[8]
AppelE, DommarajuS, SiewertB,et al. Clinical outcomes of patients with porcelain gallbladder diagnosed on CT[J]. Acad Radiol, 2021, 28Suppl 1:S22-S28. DOI: 10.1016/j.acra.2020.07.006.
[9]
KamalH, Sadr-AzodiO, EngstrandL,et al. Association between proton pump inhibitor use and biliary tract cancer risk: a Swedish population-based cohort study[J]. Hepatology, 2021, 74(4):2021-2031. DOI: 10.1002/hep.31914.
[10]
PrasaiK, TellaSH, YadavS,et al. Aspirin and statin use and the risk of gallbladder cancer[J]. Cancers(Basel), 2021, 13(5):1186. DOI: 10.3390/cancers13051186.
[11]
JacksonSS, PfeifferRM, GabbiC,et al. Menopausal hormone therapy and risk of biliary tract cancers[J]. Hepatology, 2022, 75(2):309-321. DOI: 10.1002/hep.32198.
[12]
KangJS, HongSY, HanY,et al. Limits of serum carcinoembryonic antigen and carbohydrate antigen 19-9 as the diagnosis of gallbladder cancer[J]. Ann Surg Treat Res, 2021, 101(5):266-273. DOI: 10.4174/astr.2021.101.5.266.
[13]
KimM, KimH, HanY,et al. Prognostic value of carcinoembryonic antigen(CEA) and carbohydrate antigen 19-9 (CA 19-9) in gallbladder cancer; 65 IU/mL of CA 19-9 is the new cut-off value for prognosis[J]. Cancers (Basel), 2021, 13(5):1089. DOI: 10.3390/cancers13051089.
[14]
YamamotoY, SugiuraT, OkamuraY,et al. Surgical indication for advanced gallbladder cancer considering the optimal preoperative carbohydrate antigen 19-9 cutoff value[J]. Dig Surg, 2020, 37(5):390-400. DOI: 10.1159/000506628.
[15]
LiuF, HuHJ, RegmiP,et al. Elevated platelet distribution width predicts poor prognosis in gallbladder carcinoma[J]. Cancer Manag Res, 2021, 13:4647-4655. DOI: 10.2147/CMAR.S311061.
[16]
BvP, AnwarAZ, HarshaR,et al. Role of mean platelet volume in the prognosis of gallbladder carcinoma: a tertiary centre experience[J]. Cureus, 2021, 13(7):e16389. DOI: 10.7759/cureus.16389.
[17]
KattepurAK, PatkarS, RamaswamyA,et al. Red cell distribution width and gallbladder cancer: is it really useful?[J/OL]. J Gastrointest Cancer, 2021[2022-02-06]. https:///10.1007/s12029-021-00742-7. DOI: 10.1007/s12029-021-00742-7. [published online ahead of print November 10, 2021].
[18]
YangZ, RenT, LiuS,et al. Preoperative serum fibrinogen as a valuable predictor in the nomogram predicting overall survival of postoperative patients with gallbladder cancer[J]. J Gastrointest Oncol, 2021, 12(4):1661-1672. DOI: 10.21037/jgo-21-357.
[19]
SunL, KeX, WangD,et al. Prognostic value of the albumin-to-γ-glutamyltransferase ratio for gallbladder cancer patients and establishing a nomogram for overall survival[J]. J Cancer, 2021, 12(14):4172-4182. DOI: 10.7150/jca.49242.
[20]
YaoWY, WuXS, LiuSL,et al. Preoperative lymphocyte to C-reactive protein ratio as a new prognostic indicator in patients with resectable gallbladder cancer[J/OL]. Hepatobiliary Pancreat Dis Int, 2021[2022-02-06]. https://www./science/article/abs/pii/S1499387221001624?via%3Dihub. DOI: 10.1016/j.hbpd.2021.08.006. [published online ahead of print August 27, 2021].
[21]
BaoY, YangJ, DuanY,et al. The C-reactive protein to albumin ratio is an excellent prognostic predictor for gallbladder cancer[J]. Biosci Trends, 2021, 14(6):428-435. DOI: 10.5582/bst.2020.03326.
[22]
XuB, ChenZ, ZhangJ,et al. Prognostic value of peripheral whole blood cell counts derived indexes in gallbladder carcinoma: a systematic review and meta-analysis[J]. Front Oncol, 2021, 11:707742. DOI: 10.3389/fonc.2021.707742.
[23]
KucukS, MızrakS. Diagnostic value of inflammatory factors in patients with gallbladder cancer, dysplasia, and cholecystitis[J]. Cancer Control, 2021, 28:10732748211033746. DOI: 10.1177/10732748211033746.
[24]
RoderburgC, LoosenSH, BednarschJ,et al. Levels of circulating PD-L1 are decreased in patients with resectable cholangiocarcinoma[J]. Int J Mol Sci, 2021, 22(12):6569. DOI: 10.3390/ijms22126569.
[25]
UetaE, TsutsumiK, KatoH,et al. Extracellular vesicle-shuttled miRNAs as a diagnostic and prognostic biomarker and their potential roles in gallbladder cancer patients[J]. Sci Rep, 2021, 11(1):12298. DOI: 10.1038/s41598-021-91804-0.
[26]
PriyaR, JainV, AkhtarJ,et al. Plasma-derived candidate biomarkers for detection of gallbladder carcinoma[J]. Sci Rep, 2021, 11(1):23554. DOI: 10.1038/s41598-021-02923-7.
[27]
RenJ, ChenS, YeF,et al. Exploration of differentially-expressed exosomal mRNAs, lncRNAs and circRNAs from serum samples of gallbladder cancer and xantho-granulomatous cholecystitis patients[J]. Bioengineered, 2021, 12(1):6134-6143. DOI: 10.1080/21655979.2021.1972780.
[28]
ChoiSY, KimJH, LimS,et al. CT-based nomogram for predicting survival after R0 resection in patients with gallbladder cancer: a retrospective multicenter analysis[J]. Eur Radiol, 2021, 31(5):3336-3346. DOI: 10.1007/s00330-020-07402-7.
[29]
LiuX, LiangX, RuanL,et al. A clinical-radiomics nomogram for preoperative prediction of lymph node metastasis in gallbladder cancer[J]. Front Oncol, 2021, 11:633852. DOI: 10.3389/fonc.2021.633852.
[30]
MatsumoriT, UzaN, OkadaH,et al. A novel technique for performing gallbladder tumor biopsy using a stent delivery system and biopsy forceps[J]. Endoscopy, 2020, 52(11):E415-E417. DOI: 10.1055/a-1149-8625.
[31]
KobayashiK, KobaraH, MasakiT. Novel cholangioscopy-guided targeted biopsy for diagnosing gallbladder carcinoma[J]. Dig Endosc, 2021, 33(4):e51-e53. DOI: 10.1111/den.13925.
[32]
KawaharaS, TomodaT, KatoH,et al. Accuracy of endoscopic transpapillary gallbladder drainage with liquid-based cytology for gallbladder disease[J]. Digestion, 2022, 103(2):116-125. DOI: 10.1159/000519250.
[33]
SinghiAD, NikiforovaMN, ChennatJ,et al. Integrating next-generation sequencing to endoscopic retrograde cholangiopancreatography(ERCP)-obtained biliary specimens improves the detection and management of patients with malignant bile duct strictures[J]. Gut, 2020, 69(1):52-61. DOI: 10.1136/gutjnl-2018-317817.
[34]
RenH, LuoM, ChenJ,et al. Identification of TPD52 and DNAJB1 as two novel bile biomarkers for cholangiocarcinoma by iTRAQ-based quantitative proteomics analysis[J]. Oncol Rep, 2019, 42(6):2622-2634. DOI: 10.3892/or.2019.7387.
[35]
SongX, WangX, HuY,et al. A metagenomic study of biliary microbiome change along the cholecystitis-carcinoma sequence[J]. Clin Transl Med, 2020, 10(2):e97. DOI: 10.1002/ctm2.97.
[36]
WHO Classification Of Tumours Board. WHO classification of tumours:digestive system tumours[M]. 5th ed. Lyon: International Agency for Reearch on Cancer, 2019.
[37]
AdsayV, JangKT, RoaJC,et al. Intracholecystic papillary-tubular neoplasms (ICPN) of the gallbladder (neoplastic polyps, adenomas, and papillary neoplasms that are ≥1.0 cm): clinicopathologic and immunohistochemical analysis of 123 cases[J]. Am J Surg Pathol, 2012, 36(9):1279-1301. DOI: 10.1097/PAS.0b013e318262787c.
[38]
NakanumaY, NomuraY, WatanabeH,et al. Pathological characterization of intracholecystic papillary neoplasm: a recently proposed preinvasive neoplasm of gallbladder[J]. Ann Diagn Pathol, 2021, 52:151723. DOI: 10.1016/j.anndiagpath.2021.151723.
[39]
NakanumaY, SuginoT, NomuraK,et al. Pathological features of pyloric gland adenoma of the gallbladder in comparison with gastric subtype of intracholecystic papillary neoplasm[J]. Ann Diagn Pathol, 2022, 56:151879. DOI: 10.1016/j.anndiagpath.2021.151879.
[40]
NakanumaY, SuginoT, OkamuraY,et al. Characterization of high-grade biliary intraepithelial neoplasm of the gallbladder in comparison with intracholecystic papillary neoplasm[J]. Hum Pathol, 2021, 116:22-30. DOI: 10.1016/j.humpath.2021.06.007.
[41]
MochidomeN, KogaY, OhishiY,et al. Prognostic implications of the coexisting precursor lesion types in invasive gallbladder cancer[J]. Hum Pathol, 2021, 114:44-53. DOI: 10.1016/j.humpath.2021.05.001.
[42]
MurimwaG, HesterC, MansourJC,et al. Comparative outcomes of adenosquamous carcinoma of the gallbladder: an analysis of the National Cancer Database[J]. J Gastrointest Surg, 2021, 25(7):1815-1827. DOI: 10.1007/s11605-020-04729-w.
[43]
DoMY, JangSI, KangHP,et al. Comparison of the clinical features and outcomes of gallbladder neuroendocrine carcinoma with those of adenocarcinoma: a propensity score-matched analysis[J]. Cancers(Basel), 2021, 13(18):4713. DOI: 10.3390/cancers13184713.
[44]
LvTR, HuHJ, RegmiP,et al. The effect of preoperative jaundice in the surgical management of gallbladder carcinoma: an updated Meta-analysis[J]. ANZ J Surg, 2021, 91(7-8):E455-E464. DOI: 10.1111/ans.17000.
[45]
ChaudharyRK, HiguchiR, YazawaT,et al. Resectional surgery in gallbladder cancer with jaundice-how to improve the outcome?[J]. Langenbecks Arch Surg, 2021, 406(3):791-800. DOI: 10.1007/s00423-020-02075-8.
[46]
SungMK, LeeW, LeeJH,et al. Comparing survival rate and appropriate surgery methods according to tumor location in T2 gallbladder cancer[J]. Surg Oncol, 2022, 40:101693. DOI: 10.1016/j.suronc.2021.101693.
[47]
ChenM, CaoJ, XiangY,et al. Hepatectomy strategy for T2 gallbladder cancer between segment Ⅳb and Ⅴ resection and wedge resection: a propensity score-matched study[J]. Surgery, 2021, 169(6):1304-1311. DOI: 10.1016/j.surg.2020.12.039.
[48]
TauraK. Letter to the editor regarding"Hepatectomy strategy for T2 gallbladder cancer between segment Ⅳb and Ⅴ resection and wedge resection: a propensity score-matched study" [J]. Surgery, 2021, 170(3):987-988. DOI: 10.1016/j.surg.2021.03.009.
[49]
MaithelSK. Optimal surgical management of T2 gallbladder cancer-wedge resection[J]. Surgery, 2021, 169(6):1312-1313. DOI: 10.1016/j.surg.2021.01.017.
[50]
YasukawaK, ShimizuA, MotoyamaH,et al. Applicability of sentinel lymph node oriented treatment strategy for gallbladder cancer[J]. PLoS One, 2021, 16(2):e0247079. DOI: 10.1371/journal.pone.0247079.
[51]
MiharaK, MatsudaS, NakamuraY,et al. Intraoperative laparoscopic detection of sentinel lymph nodes with indocyanine green and superparamagnetic iron oxide in a swine gallbladder cancer model[J]. PLoS One, 2021, 16(3):e0248531. DOI: 10.1371/journal.pone.0248531.
[52]
LiuF, LiFY. Puzzle and challenge in routine extrahepatic bile duct resection for advanced gallbladder carcinoma[J]. Gut Liver, 2020, 14(6):850-851. DOI: 10.5009/gnl20150.
[53]
FancelluA, SannaV, DeianaG,et al. Current role of hepatopancreatoduodenectomy for the management of gallbladder cancer and extrahepatic cholangiocarcinoma: a systematic review[J]. World J Gastrointest Oncol, 2021, 13(6):625-637. DOI: 10.4251/wjgo.v13.i6.625.
[54]
孙旭恒, 任泰, 耿亚军,等. 中国胆囊癌外科治疗现状与病理学特征多中心回顾性研究(附4345例报告)[J]. 中国实用外科杂志, 2021, 41(1):99-106. DOI: 10.19538/j.cjps.issn1005-2208.2021.01.18.
[55]
ĐokicM, StupanU, LicenS,et al. Residual disease in lymph nodes has no influence on survival in patients with incidental gallbladder cancer-institution experience with literature review[J]. Radiol Oncol, 2021, 56(2):208-215. DOI: 10.2478/raon-2021-0048.
[56]
AndoT, SakataJ, NomuraT,et al. Anatomic location of residual disease after initial cholecystectomy independently determines outcomes after re-resection for incidental gallbladder cancer[J]. Langenbecks Arch Surg, 2021, 406(5):1521-1532. DOI: 10.1007/s00423-021-02165-1.
[57]
PatkarS, PatelS, GuptaA,et al. Revision surgery for incidental gallbladder cancer-challenging the dogma: ideal timing and real-world applicability[J]. Ann Surg Oncol, 2021, 28(11):6758-6766. DOI: 10.1245/s10434-021-09687-4.
[58]
KhanTM, VerbusEA, HongH,et al. Perioperative versus adjuvant chemotherapy in the management of incidentally found gallbladder cancer (OPT-IN)[J]. Ann Surg Oncol, 2022, 29(1):37-38. DOI: 10.1245/s10434-021-10277-7.
[59]
CaoJ, WangY, ZhangB,et al. Comparison of outcomes after primary laparoscopic versus open approach for T1b/T2 gallbladder cancer[J]. Front Oncol, 2021, 11:758319. DOI: 10.3389/fonc.2021.758319.
[60]
LeeW, KimKM, KwakBJ,et al. Clinical outcomes between a minimally invasive and open extended cholecystectomy for T2 gallbladder cancer: a propensity score matching analysis[J/OL]. J Laparoendosc Adv Surg Tech A, 2021[2022-02-06]. https://www./doi/10.1089/lap.2021.0417?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed. DOI: 10.1089/lap.2021.0417. [published online ahead of print August 11, 2021].
[61]
ZhangW, CheX. Feasibility and Safety of Laparoscopic treatment for early and T3 stage gallbladder cancer: a systematic review[J]. Surg Laparosc Endosc Percutan Tech, 2020, 31(1):113-123. DOI: 10.1097/SLE.0000000000000852.
[62]
TschuorC, PickensRC, IsenbergEE,et al. Robotic resection of gallbladder cancer: a single-center retrospective comparative study to open resection[J]. Am Surg, 2021:31348211047491. DOI: 10.1177/00031348211047491.
[63]
ChenX, WangD, LiuJ,et al. Genomic alterations in biliary tract cancer predict prognosis and immunotherapy outcomes[J]. J Immunother Cancer, 2021, 9(11):e003214. DOI: 10.1136/jitc-2021-003214.
[64]
YoonJG, KimMH, JangM,et al. Molecular characterization of biliary tract cancer predicts chemotherapy and programmed death 1/programmed death-ligand 1 blockade responses[J]. Hepatology, 2021, 74(4):1914-1931. DOI: 10.1002/hep.31862.
[65]
AziziAA, LamarcaA, McNamaraMG,et al. Chemotherapy for advanced gallbladder cancer(GBC):a systematic review and Meta-analysis[J]. Crit Rev Oncol Hematol, 2021, 163:103328. DOI: 10.1016/j.critrevonc.2021.103328.
[66]
ValleJ, WasanH, PalmerDH,et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer[J]. N Engl J Med, 2010, 362(14):1273-1281. DOI: 10.1056/NEJMoa0908721.
[67]
CuiXY, LiXC, CuiJJ,et al. Modified FOLFIRINOX for unresectable locally advanced or metastatic gallbladder cancer, a comparison with GEMOX regimen[J]. Hepatobiliary Surg Nutr, 2021, 10(4):498-506. DOI: 10.21037/hbsn-20-846.
[68]
SharmaA, PramanikR, KumarA,et al. Safety and efficacy of modified FOLFIRINOX in unresectable or metastatic gallbladder cancer: a phase Ⅱ pilot study[J]. JCO Glob Oncol, 2021, 7:820-826. DOI: 10.1200/GO.20.00657.
[69]
PhelipJM, DesrameJ, EdelineJ,et al. Modified FOLFIRINOX versus CISGEM chemotherapy for patients with advanced biliary tract cancer(PRODIGE 38 AMEBICA): a randomized phase Ⅱ study[J]. J Clin Oncol, 2022, 40(3):262-271. DOI: 10.1200/JCO.21.00679.
[70]
LamarcaA, PalmerDH, WasanHS,et al. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer(ABC-06): a phase 3, open-label, randomised, controlled trial[J]. Lancet Oncol, 2021, 22(5):690-701. DOI: 10.1016/S1470-2045(21)00027-9.
[71]
YooC, KimKP, JeongJH,et al. Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study[J]. Lancet Oncol, 2021, 22(11):1560-1572. DOI: 10.1016/S1470-2045(21)00486-1.
[72]
TalwarV, RainaS, GoelV,et al. Nab-paclitaxel: an effective third-line chemotherapy in patients with advanced, unresectable gallbladder cancer[J]. Indian J Med Res, 2020, 152(5):475-481. DOI: 10.4103/ijmr.IJMR_930_18.
[73]
LiangH, WangY, ChenJ,et al. The efficacy of adjuvant chemoradiotherapy in early-stage gallbladder adenocarcinoma depends on the tumor invasion depth and differentiation level[J]. Front Oncol, 2020, 10:616170. DOI: 10.3389/fonc.2020.616170.
[74]
LeeSU, SeongJ, KimTH,et al. Role of adjuvant chemoradiotherapy and chemotherapy in patients with resected gallbladder carcinoma: a multi-institutional analysis(KROG 19-04) [J/OL]. Cancer Biol Med, 2021 [2022-02-06]. http://www./index.php/cocr/article/view/1999/1977. DOI: 10.20892/j.issn.2095-3941.2020.0667. [published online ahead of print December 20,2021].
[75]
CaiYL, LinYX, XiongXZ,et al. Postsurgical radiotherapy in stage ⅢB gallbladder cancer patients with one to three lymph nodes metastases: a propensity score matching analysis[J]. Am J Surg, 2021, 221(3):642-648. DOI: 10.1016/j.amjsurg.2020.08.007.
[76]
JavleM, BoradMJ, AzadNS,et al. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer(MyPathway): a multicentre, open-label, phase 2a, multiple basket study[J]. Lancet Oncol, 2021, 22(9):1290-1300. DOI: 10.1016/S1470-2045(21)00336-3.
[77]
JavleMM, OhDY, IkedaM,et al. Varlitinib plus capecitabine in second-line advanced biliary tract cancer: a randomized, phase Ⅱ study (TreeTopp)[J]. ESMO Open, 2022, 7(1):100314. DOI: 10.1016/j.esmoop.2021.100314.
[78]
ZhengQ, WuC, YeH,et al. Analysis of the efficacy and prognostic factors of PD-1 inhibitors in advanced gallbladder cancer[J]. Ann Transl Med, 2021, 9(20):1568. DOI: 10.21037/atm-21-4747.
[79]
ZhangQ, LiuX, WeiS,et al. Lenvatinib plus PD-1 inhibitors as first-line treatment in patients with unresectable biliary tract cancer: a single-arm, open-label, phase Ⅱ study[J]. Front Oncol, 2021, 11:751391. DOI: 10.3389/fonc.2021.751391.
[80]
ChiangN, BaiL, ChenL, et al. A phase Ⅱ trial of nivolumab and gemcitabine and S-1 as the first-line treatment in patients with advanced biliary tract cancer[J]. Ann Oncol, 2021, 32Suppl 5:S376-S381. DOI: 10.1016/annonc/annonc685.
[81]
ZongH, ZhongQ, ZhaoR,et al. Phase Ⅱ study of anlotinib plus sintlimab as second-line treatment for patients with advanced biliary tract cancers[J]. J Clin Oncol, 2021, 39(3_suppl):307. DOI: 10.1200/JCO.2021.39.3_suppl.307.
[82]
CousinS, BelleraCA, GuéganJP, et al. Regomune: a phase Ⅱ study of regorafenib+avelumab in solid tumors—results of the biliary tract cancer(BTC) cohort[J]. J Clin Oncol, 2021, 39(15Suppl):4096. DOI: 10.1200/JCO.2021.39.15_suppl.4096.
[83]
LuisV, ZarnieL, HyunC, et al. Lenvatinib plus pembrolizumab for patients with previously treated biliary tract cancers in the multicohort phase 2 LEAP-005 study[J]. J Clin Oncol, 2021, 39(15Suppl):4080. DOI: 10.1200/JCO.2021.39.15_suppl.4080.